These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053 [TBL] [Abstract][Full Text] [Related]
9. Warfarin pharmacogenomics: current best evidence. Kimmel SE J Thromb Haemost; 2015 Jun; 13 Suppl 1():S266-71. PubMed ID: 26149035 [TBL] [Abstract][Full Text] [Related]
10. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498 [TBL] [Abstract][Full Text] [Related]
11. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237 [TBL] [Abstract][Full Text] [Related]
14. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial. Makar-Aušperger K; Krželj K; Lovrić Benčić M; Radačić Aumiler M; Erdeljić Turk V; Božina N Ther Drug Monit; 2018 Jun; 40(3):362-368. PubMed ID: 29494423 [TBL] [Abstract][Full Text] [Related]
15. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Scott SA; Edelmann L; Kornreich R; Desnick RJ Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229 [TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Hillman MA; Wilke RA; Yale SH; Vidaillet HJ; Caldwell MD; Glurich I; Berg RL; Schmelzer J; Burmester JK Clin Med Res; 2005 Aug; 3(3):137-45. PubMed ID: 16160068 [TBL] [Abstract][Full Text] [Related]
17. Genotype-guided dosing of warfarin through modeling and simulation. Deng J; Vozmediano V; Rodriguez M; Cavallari LH; Schmidt S Eur J Pharm Sci; 2017 Nov; 109S():S9-S14. PubMed ID: 28502675 [TBL] [Abstract][Full Text] [Related]
18. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]. Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278 [TBL] [Abstract][Full Text] [Related]
19. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313 [TBL] [Abstract][Full Text] [Related]